Q-omics provides the consensus-scored NGDN profile across patient tissues and cancer cell-line models. NGDN expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NGDN is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, NGDN protein abundance shows 29,521 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, BLCA, and LSCC as cancer lineages where NGDN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NGDN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NGDN survival associations across molecular data types. NGDN RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NGDN RNA expression–survival associations across cancer types. High NGDN expression shows unfavorable associations in ACC, HNSC and LIHC, but favorable associations in BRCA, KIRC and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NGDN RNA expression.
This table summarizes NGDN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NGDN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NGDN shows lower tumor expression in THCA and higher tumor expression in BLCA, LIHC, HNSC, COAD and STAD. The BLCA box plot shows higher NGDN RNA expression in tumor versus normal tissue (log2 FC = +0.512, t-test p < 0.001).
This table shows molecular features associated with NGDN in patient tissues and cancer cell lines. In patient samples, NGDN shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NGDN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and SKIN.
